Paladin Partners’s MiNK Therapeutics INKT Stock Holding History

Paladin Partners’s Portfolio INKT Stock Details INKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6.28K	Sell	500 -500	-50%	-$5.68K	﹤0.01%	138
2026 Q2	$11.7K	Hold	1,000	–	–	0.01%	131
2026 Q1	$10.5K	Hold	1,000	–	–	0.01%	128
2025 Q4	$11.2K	Buy	+1,000	New	+$12.9K	0.01%	127

Paladin Partners's INKT Position: Q3 2026 in Review

Paladin Partners reduced its MiNK Therapeutics (INKT) stake by 50% in Q3 2026, selling an estimated $5.68K and leaving 500 shares worth $6.28K. The position accounts for ﹤0.01% of the portfolio, ranked #138.

Paladin Partners first reported a position in INKT in Q4 2025 and has held it in 4 quarters since. The position peaked at $11.7K in Q2 2026. 1 fund tracked by Wall St. Rank holds INKT as of Q3 2026.

Paladin Partners held 500 shares of MiNK Therapeutics worth $6.28K as of Q3 2026.
Paladin Partners sold 500 MiNK Therapeutics shares in Q3 2026, an estimated $5.68K.
MiNK Therapeutics made up ﹤0.01% of Paladin Partners's portfolio in Q3 2026, its #138 holding.
Paladin Partners first reported a position in MiNK Therapeutics in Q4 2025 and has held it in 4 quarters since.
Paladin Partners's MiNK Therapeutics position peaked at $11.7K in Q2 2026.
1 fund tracked by Wall St. Rank held MiNK Therapeutics as of Q3 2026.

Based on Paladin Partners's 13F filing for Q3 2026, filed 6 Oct 2026.